Introduction
The kidneys function in a wide variety of ways necessary for health. They excrete metabolic waste, regulate fluid and electrolyte balance, promote bone integrity, and more. These two bean-shaped organs interact with the cardiovascular system to maintain hemodynamic stability. Renal blood flow (RBF) and glomerular filtration are important aspects of sustaining proper organ functions. A delicate balance exists between renal blood flow and the glomerular filtration rate as changes in one may affect the other.
Function
Register For Free And Read The Full Article
- Search engine and full access to all medical articles
- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Function
An important interplay between RBF and proper kidney functioning is the renin-angiotensin-aldosterone system, also known as RAAS. Renin is secreted by juxtaglomerular cells in response to decreased renal arterial pressure, increased renal sympathetic activation from beta-1 adrenergic receptors, or decreased sodium delivery to macula densa cells.[1] Renin converts angiotensinogen which is made in the liver to angiotensin I. Angiotensin-converting enzyme (ACE) produced by the lungs then converts angiotensin I into angiotensin II. Angiotensin II plays many different roles. It acts on angiotensin II receptors to induce vasoconstriction and increase blood pressure. It also preferentially constricts efferent arterioles to increase the filtration when RBF is low. Angiotensin II also induces the expression of aldosterone in the adrenal cortex which increases sodium channel insertion, increases the activity of sodium/potassium pump, enhances potassium and hydrogen excretion in principal cells. These simultaneous effects act to create a gradient for sodium and water reabsorption. Another important effect of angiotensin II is to increase expression of antidiuretic hormone (ADH) in the posterior pituitary which inserts aquaporin channels on the apical membrane of principal cells for water absorption. Interestingly, it stimulates the hypothalamus to increase thirst, which may be one of the body’s mechanisms of signaling low volume states or dehydration.[2]
Mechanism
RBF originates at the hilum of the kidney through the renal artery. From the segmental artery to the interlobar artery, blood arrives parallel to the corticomedullary junction in the arcuate artery. This gives rise to the interlobular arteries that radiate toward the surface. Afferent arterioles branch off which ultimately leads into the glomerulus of Bowman’s capsule. From here, efferent arterioles begin to form the venous system and subdivide into another set of capillaries known as the peritubular capillaries. Blood then leaves the kidney and enters the venous circulation. However, efferent arterioles that are located above the corticomedullary border travel downward into the medulla. They further divide into vasa recta which surround the Loop of Henle. The purpose of these vessels is to supply capillaries located in the medulla. Differences between blood flow of the renal cortex and medulla play a significant role in the regulation of tubular osmolality. High blood flow and the peritubular capillaries in the cortex maintain a similar interstitial environment of the renal cortical tubules with that of blood plasma. However, in the medulla, the interstitial environment is different than that of blood plasma.[3] This crucial difference plays a significant role in the medullary osmotic gradient and regulation of water excretion.
RBF comprises roughly 20% of the total cardiac output; it is roughly 1 liter per minute. Flow in the kidney follows the same hemodynamic principles seen elsewhere in other organs. RBF is proportional to the difference in pressures between the renal artery and vein, but inversely proportional to the vasculature resistance. Resistance is influenced by whether a vessel is in series or in parallel. Because the kidney has vasculature that is parallel, the total resistance is decreased, thus accounting for the higher blood flow.
The glomerular filtration rate (GFR) is the amount of fluid filtered from the glomerulus into Bowman’s capsule per unit time. It indicates the condition of the kidney and can be used to help guide management in cases such as chronic kidney disease. The glomerular filtration barrier is uniquely designed to prevent the passage of certain substances according to size and charge. It is composed of an inner layer of fenestrated capillary endothelium which is freely permeable to everything except for blood cells and 100 nm or greater molecules. The middle layer is a basement membrane composed of type IV collagen and heparan sulfate. The outermost epithelial layer consists of podocyte foot processes interposed with the basement membrane. It prevents the entry of molecules greater than 50 to 60 nm. All layers contain negatively charged glycoproteins that also aid in preventing the entry of other negatively charged molecules, most notably albumin.
The GFR can be determined by the Starling equation, which is the filtration coefficient multiplied by the difference between glomerular capillary oncotic pressure and Bowman space oncotic pressure subtracted from the difference between glomerular capillary hydrostatic pressure and Bowman space hydrostatic pressure. Increases in the glomerular capillary hydrostatic pressure cause increases in net filtration pressure and GFR. However, increases in Bowman space hydrostatic pressure causes decreases in filtration pressure and GFR. This may result from ureteral constriction. Increases in protein concentration raise glomerular capillary oncotic pressure and draw in fluids through osmosis, thus decreasing GFR.
Filtration fraction (FF) is the fraction of renal plasma flow (RPF) filtered across the glomerulus. The equation is GFR divided by RPF. FF is about 20% which indicates the remaining 80% continues its pathway through the renal circulation. When the filtration fraction increases, the protein concentration of the peritubular capillaries increases. This leads to additional absorption in the proximal tubule. Instead, when the filtration fraction decreases, the amount of fluid being filtered across the glomerular filtration barrier per unit time decreases as well. The protein concentration downstream in the peritubular vessels decreases and the absorptive capacity of the proximal tubules lessens as well.
The kidneys have mechanisms designed to preserve GFR within a certain range. If GFR is too low, metabolic wastes will not get filtered from the blood into the renal tubules. If GFR is too high, the absorptive capacity of salt and water by the renal tubules becomes overwhelmed. Autoregulation manages these changes in GFR and RBF. There are two mechanisms by which this occurs. The first is called the myogenic mechanism. During the increased stretch, the renal afferent arterioles contract to decrease GFR. The second mechanism is called the tubuloglomerular feedback. These mechanisms have an important interplay as they each create individual oscillations, causing a synchronized propagating electrical signal among nephrons. [4] Increased renal arterial pressure increases the delivery of fluid and sodium to the distal nephron where the macula densa is located.[5] It senses the flow and sodium concentration. ATP is released and calcium increases in granular and smooth muscle cells of the afferent arteriole. This causes arteriole constriction and decreased renin release. This overall process helps decrease GFR and maintain it in a limited range, albeit slightly higher than baseline. If low GFR is present, there is decreased fluid flow and sodium delivery. The macula densa responds by decreasing ATP release, and there is a subsequent decrease in calcium from the smooth muscle cells of the afferent arteriole. The ensuing result is vasodilation, and increased renin release in an attempt to increase GFR. The autoregulatory pressure range is between 80 to 180 mm Hg. Outside of this range, these mechanisms mentioned above fail.
Related Testing
RPF = Clearance of para-aminohippuric acid (PAH) = [U][V] / [P]
[U] is the urine concentration of PAH in mg/mL
[V] is the urine flow rate in mL per minute
[P] is the plasma concentration of PAH in mg/mL
RBF = RPF / (1 - Hematocrit)
In this equation, the denominator denotes the amount of blood volume occupied by plasma.
Pathophysiology
The function of the kidneys is related to the cardiovascular system. Certain cardiac pathologies that cause systolic dysfunction and impaired forward flow lead to decreases in RBF. This, in turn, activates RAAS in an effort to maintain blood pressure. Long-standing activation of RAAS can lead to abnormally elevated blood pressure, excessive vasoconstriction, vascular hypertrophy, and fibrosis. It has been reported that the blockade of RAAS has been beneficial in patients with chronic systolic heart failure. Studies have shown that the administration of angiotensin II in mice models served as a protective mechanism in preventing kidney damage. [6] In certain glomerular diseases such as nephrotic syndrome, anionic glycoproteins in the filtration barrier may be removed, decreasing the selective charge and resulting in proteinuria. Another aspect that regulates renal blood flow is the renal afferent and efferent nerves. When sympathetic activity is increased, it contributes to renal hypertension and end-stage renal disease. Studies have shown that catheter-based sympathetic denervation improved blood pressure.[7]
Clinical Significance
Changes in glomerular dynamics are important factors for clinicians to consider when evaluating the effects of diverse pathologies on the kidney. Afferent arteriole constriction leads to decreased GFR and decreased RPF, resulting in no change in FF. One important function of prostaglandins is to dilate the afferent arteriole. Thus when non-steroidal anti-inflammatory drugs (NSAID) are administered to patients, these changes in the glomerulus are to be expected because NSAIDs reduce the formation of prostaglandins.[8] Thus, in a patient exhibiting signs and symptoms of kidney disease, clinicians should take caution in prescribing NSAIDs. During efferent arteriole constriction, GFR is increased, but RPF is decreased, resulting in increased filtration fraction. During a state of increased plasma protein concentration such as during multiple myeloma, GFR is decreased with no change in RPF, resulting in decreased FF. However, during a state of decreased plasma protein concentration such as during nephrotic syndrome, GFR is increased with no change in RPF, resulting in increased FF. Constriction of a ureter such as during nephrolithiasis may lead to decreased GFR with no change in RPF, resulting in decreased FF. Finally, during low-volume states as in dehydration, GFR is decreased, but RPF is decreased to a much larger extent. This results in an increased FF.
One of the most commonly used medications for patients with diabetes or heart failure is an ACE inhibitor. It reduces the formation of angiotensin II, which in turn decreases GFR by preventing the constriction of efferent arterioles. Because ACE inactivates bradykinin, a potent vasodilator, a side effect of using an ACE inhibitor is angioedema from increased bradykinin levels. Another common adverse reaction is a cough. Patients with intolerance should be switched to angiotensin II receptors blockers (ARBs).
In patients with chronic kidney disease undergoing anesthesia, care should be taken to maintain renal perfusion pressures as certain agents are known to decrease the GFR and cause renal injury such as methoxyflurane.[9] Additionally, the dosage of anesthetic medications should be carefully titrated in patients with renal failure. For instance, vecuronium has an active metabolite that may prolong the duration of the dose in renal failure and should be adjusted to minimize adverse effects.[10]
References
Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. Journal of veterinary internal medicine. 2019 Mar:33(2):363-382. doi: 10.1111/jvim.15454. Epub 2019 Feb 26 [PubMed PMID: 30806496]
Bichet DG. Vasopressin and the Regulation of Thirst. Annals of nutrition & metabolism. 2018:72 Suppl 2():3-7. doi: 10.1159/000488233. Epub 2018 Jun 20 [PubMed PMID: 29925072]
Pallone TL, Edwards A, Mattson DL. Renal medullary circulation. Comprehensive Physiology. 2012 Jan:2(1):97-140. doi: 10.1002/cphy.c100036. Epub [PubMed PMID: 23728972]
Level 3 (low-level) evidenceMarsh DJ, Postnov DD, Sosnovtseva OV, Holstein-Rathlou NH. The nephron-arterial network and its interactions. American journal of physiology. Renal physiology. 2019 May 1:316(5):F769-F784. doi: 10.1152/ajprenal.00484.2018. Epub 2019 Feb 13 [PubMed PMID: 30759020]
Wang H, Romero CA, Masjoan Juncos JX, Monu SR, Peterson EL, Carretero OA. Effect of salt intake on afferent arteriolar dilatation: role of connecting tubule glomerular feedback (CTGF). American journal of physiology. Renal physiology. 2017 Dec 1:313(6):F1209-F1215. doi: 10.1152/ajprenal.00320.2017. Epub 2017 Aug 23 [PubMed PMID: 28835421]
Papinska AM, Rodgers KE. Long-Term Administration of Angiotensin (1-7) to db/db Mice Reduces Oxidative Stress Damage in the Kidneys and Prevents Renal Dysfunction. Oxidative medicine and cellular longevity. 2018:2018():1841046. doi: 10.1155/2018/1841046. Epub 2018 Oct 23 [PubMed PMID: 30425780]
Sata Y, Head GA, Denton K, May CN, Schlaich MP. Role of the Sympathetic Nervous System and Its Modulation in Renal Hypertension. Frontiers in medicine. 2018:5():82. doi: 10.3389/fmed.2018.00082. Epub 2018 Mar 29 [PubMed PMID: 29651418]
Rotunno R, Oppo I, Saetta G, Aveta P, Bruno S. NSAIDs and heart failure: A dangerous relationship. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace. 2018 Jun 7:88(2):950. doi: 10.4081/monaldi.2018.950. Epub 2018 Jun 7 [PubMed PMID: 29877658]
Dayan AD. Analgesic use of inhaled methoxyflurane: Evaluation of its potential nephrotoxicity. Human & experimental toxicology. 2016 Jan:35(1):91-100. doi: 10.1177/0960327115578743. Epub 2015 Apr 28 [PubMed PMID: 25926525]
Tarbeeh GA, Othman MM. The pharmacodynamics of vecuronium in chronic renal failure patients: the impact of different priming doses. Renal failure. 2012:34(7):827-33. doi: 10.3109/0886022X.2012.684552. Epub 2012 May 18 [PubMed PMID: 22607043]
Level 1 (high-level) evidence